Europese Unie - Nederlands - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastro-intestinale stromale tumoren - antineoplastische middelen - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Europese Unie - Nederlands - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastro-intestinale stromale tumoren - andere antineoplastische middelen, proteïne kinase remmers - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Europese Unie - Nederlands - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinoom, niet-kleincellige long - antineoplastische middelen - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Europese Unie - Nederlands - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinoom, niet-kleincellige long - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Europese Unie - Nederlands - EMA (European Medicines Agency)

roche registration gmbh - alectinib hydrochloride - carcinoom, niet-kleincellige long - antineoplastische middelen - alecensa als monotherapie is geïndiceerd voor eerstelijns behandeling van volwassen patiënten met een anaplastisch lymfoom kinase (alk)-positieve gevorderde niet-kleincellige longkanker (niet-kleincellig longcarcinoom). alecensa als monotherapie is geïndiceerd voor de behandeling van volwassen patiënten met alk‑positieve gevorderde niet-kleincellig longcarcinoom eerder behandeld met crizotinib.

Europese Unie - Nederlands - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinoom, niet-kleincellige long - antineoplastische middelen - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - ceritinib - carcinoom, niet-kleincellige long - antineoplastische middelen - zykadia is geïndiceerd voor de behandeling van volwassen patiënten met anaplastisch lymfoomkinase (alk) -positieve, geavanceerde niet-kleincellige longkanker (nsclc) die eerder met crizotinib werden behandeld..

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

centrafarm b.v. van de reijtstraat 31-e 4814 ne breda - fluconazol 150 mg/stuk - capsule, hard - gelatine (e 441) ; lactose 1-water ; magnesiumstearaat (e 470b) ; siliciumdioxide (e 551) ; starch, pregelatinised (not from wheat starch) ; titaandioxide (e 171), - fluconazole

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. - lopinavir ; ritonavir - filmomhulde tablet - copovidon ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; macrogol 3350 ; macrogol 400 ; natriumstearylfumaraat ; polysorbaat 80 (e 433) ; siliciumdioxide (e 551) ; sorbitanmonolauraat (e 493) ; talk (e 553 b) ; titaandioxide (e 171), - lopinavir and ritonavir